Results 111 to 120 of about 15,740 (203)

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi‐Country Needs Assessment

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The treatment landscape for relapse/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) has evolved with recent novel agents. With the availability of novel agents that slow disease progression, managing treatment side effects and monitoring response in patients with these hematologic malignancies may ...
Patrice Lazure, Toby A. Eyre, Carsten Utoft Niemann, Nirav N. Shah, Martin Dreyling, Florence Cymbalista, Sophie Peloquin, Serge Znamensky, Benjamin Goebel, Suzanne Murray   +9 more
wiley   +1 more source

Integrative multi‐omics analysis prioritizes DPEP1 as a genetically supported candidate associated with skin cancer risk

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
Flowchart of the study design outlining target identification, validation, and subsequent functional and translational characterization. Abstract Background Skin cancer (SC) is among the most prevalent malignancies, yet causal circulating proteins and tractable therapeutic targets remain poorly defined.
Fan Shen, Yongkai Yu, Zongfeng Liao, Liye Mao, Qianyun Wang, Wanju Wang, Yuanhui Liu, Ling Li   +7 more
wiley   +1 more source

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li, Qiurong Zhang, Xiaoyan Li, Lin Liu, Yonglin Shen, Yu Li, Lihui Peng, Chaoyang Zhou, Chie Qiu, Zhongtao Yuan, Shiqian Hou, Youcheng Wang, Lihua Zhang, Jingqiong Li, Liang Zhao, Qiuyuan Tang, Zucong Chen, Jing Feng, Xuejuan Zhang, Guoxiu Bao, Kui Zhang, Renpeng Zhang, Shiqi Li, Yingnian Chen, Jianhua Rao, Yancheng Dong, Dingsong Zhang, Yueyuan Wang, Aifang Li, Xi Ye, Lei Lei, Jiao Chen, Sufen Xu, Yanling Jin, Chaoen Zheng, Yang Liang, Sanbin Wang   +36 more
wiley   +1 more source

Salvage With Revumenib: Targeting KMT2A‐Rearranged Isolated Leukemia Cutis Identified in the Extramedullary Disease

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a high risk of relapse. Leukemia cutis is characterized by the presence of neoplastic leukocytes infiltrating the skin. Here, we present a previously treated AML patient who relapsed with isolated leukemia cutis without bone marrow involvement. Fluorescence in
Bana Antonios, Xuemei Wu, Lynn Johnson, Avani Ahuja, Megan Blauvelt, Margaret Aronckes, Nina Dutton, Jennifer Dujmic, Salman Fazal, Taimoor I. Sheikh   +9 more
wiley   +1 more source

Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T‐Cell Therapy in TP53‐Deleted CLL: A Case Report

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Cutaneous manifestations of chronic lymphocytic leukemia (CLL) are heterogeneous and may result from leukemic infiltration, secondary malignancies, infectious complications, or reactive inflammatory processes. Reactive angioendotheliomatosis (RAE) is a rare vascular proliferation that has only infrequently been reported in association with ...
Feras Alfraih, Mostafa F. Mohammed Saleh, David Li, Razan Mohty, Mohamed Kharfan‐Dabaja   +4 more
wiley   +1 more source

Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection‐related mortality remains a significant concern for patients' overall survival (OS). Methods This Swedish, population‐based study examined incidence of infections and OS in
Ingrid Glimelius, Love Tätting, Jonatan Freilich, M. Natalia Stelmaszuk, Qian Yang, Anna Deleskog, Sigurður Y. Kristinsson   +6 more
wiley   +1 more source

Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?

American Journal of Hematology, Volume 101, Issue 8, Page 1783-1789, August 2026.
Sudhir Tauro, Ayalew Tefferi
wiley   +1 more source

DNMT3A Co‐Mutation and Real‐World Clinical Outcomes With Gilteritinib in FLT3‐Mutated Acute Myeloid Leukaemia Across Molecular Subgroups

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction: Molecular co‐mutations modulate outcomes in FLT3‐mutated AML treated with gilteritinib; real‐world data stratified by DNMT3A co‐mutation status are lacking. Methods We retrospectively analysed 29 adults with R/R FLT3‐mutated AML treated at two Italian centres.
Francesca Duca, Beatrice Manghisi, Andrea Palasciano, Anna Mochi, Matteo Parma, Rosa Greco, Roberto Cairoli, Carlo Gambacorti‐Passerini, Monica Fumagalli   +8 more
wiley   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source